Prostate cancer screening

Area of Science:

• Urology
• Preventive Medicine
• Public Health

Background:

• Universal screening for prostate cancer (Pca) using prostate-specific antigen (PSA) testing is controversial.
• Current guidelines often do not recommend routine Pca screening due to potential harms like overdiagnosis and overtreatment.
• The balance between screening benefits and risks requires careful consideration.

Purpose of the Study:

• To evaluate the current recommendations and rationale against universal prostate cancer screening.
• To emphasize the importance of shared decision-making in Pca screening discussions.
• To explore how new healthcare models can support preventive service delivery.

Main Methods:

• Review of current literature and guidelines on prostate cancer screening.
• Analysis of the risks (overdiagnosis, overtreatment) versus benefits of PSA testing.
• Discussion of shared decision-making principles in clinical practice.

Main Results:

• Universal PSA-based screening for prostate cancer is not recommended.
• The harms associated with overdiagnosis and overtreatment are considered to outweigh the benefits.
• Shared decision-making is essential for patients considering Pca screening.

Conclusions:

• A paradigm shift is needed in Pca screening, focusing on risks over undetected cancer.
• Physicians should engage in shared decision-making with patients regarding Pca screening preferences and risk profiles.
• Healthcare models, including those influenced by the Patient Protection and Affordable Care Act, aim to facilitate preventive care.